Tompkins Financial Corp Lowers Position in Amgen Inc. (NASDAQ:AMGN)

Tompkins Financial Corp cut its position in shares of Amgen Inc. (NASDAQ:AMGNFree Report) by 1.2% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 27,422 shares of the medical research company’s stock after selling 340 shares during the quarter. Tompkins Financial Corp’s holdings in Amgen were worth $6,088,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Tanglewood Legacy Advisors LLC bought a new stake in Amgen during the fourth quarter worth about $26,000. Ruedi Wealth Management Inc. bought a new stake in shares of Amgen in the 4th quarter worth approximately $27,000. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Amgen in the 1st quarter worth approximately $28,000. GW&K Investment Management LLC increased its position in Amgen by 200.0% during the 4th quarter. GW&K Investment Management LLC now owns 120 shares of the medical research company’s stock valued at $32,000 after buying an additional 80 shares in the last quarter. Finally, General Partner Inc. bought a new position in Amgen during the 1st quarter valued at approximately $32,000. 74.44% of the stock is owned by hedge funds and other institutional investors.

Amgen Stock Performance

NASDAQ AMGN traded up $1.50 during trading hours on Tuesday, hitting $264.65. 408,990 shares of the company’s stock traded hands, compared to its average volume of 2,447,513. Amgen Inc. has a 52 week low of $211.71 and a 52 week high of $296.67. The firm has a market capitalization of $141.56 billion, a P/E ratio of 17.74, a P/E/G ratio of 3.28 and a beta of 0.61. The company has a current ratio of 2.77, a quick ratio of 2.48 and a debt-to-equity ratio of 8.76. The business’s fifty day moving average price is $248.12 and its two-hundred day moving average price is $237.72.

Amgen (NASDAQ:AMGNGet Free Report) last issued its quarterly earnings data on Thursday, August 3rd. The medical research company reported $5.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.44 by $0.56. The firm had revenue of $7 billion during the quarter, compared to the consensus estimate of $6.66 billion. Amgen had a net margin of 30.02% and a return on equity of 196.60%. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $4.65 EPS. Equities research analysts predict that Amgen Inc. will post 18.35 EPS for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Friday, August 18th were paid a dividend of $2.13 per share. The ex-dividend date of this dividend was Thursday, August 17th. This represents a $8.52 dividend on an annualized basis and a dividend yield of 3.22%. Amgen’s dividend payout ratio (DPR) is presently 57.45%.

Insider Buying and Selling

In other Amgen news, EVP Murdo Gordon sold 9,558 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $262.43, for a total value of $2,508,305.94. Following the completion of the transaction, the executive vice president now directly owns 44,308 shares in the company, valued at $11,627,748.44. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.57% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

AMGN has been the subject of a number of analyst reports. raised Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 8th. Credit Suisse Group reduced their price objective on Amgen from $220.00 to $200.00 in a research report on Wednesday, July 12th. Royal Bank of Canada raised their price objective on Amgen from $250.00 to $253.00 and gave the company a “sector perform” rating in a research report on Friday, August 4th. Oppenheimer reaffirmed an “outperform” rating and set a $280.00 price objective on shares of Amgen in a research report on Tuesday, July 25th. Finally, Jefferies Financial Group raised their price objective on Amgen from $275.00 to $310.00 and gave the company a “buy” rating in a research report on Monday, August 14th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Amgen has a consensus rating of “Moderate Buy” and an average target price of $265.44.

Read Our Latest Analysis on Amgen

Amgen Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh├žet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.

See Also

Want to see what other hedge funds are holding AMGN? Visit to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGNFree Report).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with's FREE daily email newsletter.